CROI 2017: Bone Density Improves in People Who Switch from Tenofovir DF to Tenofovir Alafenamide

Posted in Latest News on

Bone DensityAfter 3 years, tenofovir alafenamide (TAF) for first-line HIV treatment was better at suppressing viral load and safer for the bones and kidneys than the older tenofovir disoproxil fumarate (TDF), researchers reported at the 2017 Conference on Retroviruses and Opportunistic Infections (CROI) in February in Seattle. Another study showed that people with low bone density who switched from TDF to TAF saw improved bone health, including a reduction in osteoporosis. (Image © Russell Kightley)

Gilead Sciences’ TDF (Viread, also in the Truvada, Atripla, Complera, and Stribild coformulations) has been one of the most widely used antiretroviral drugs. It is generally considered safe and well-tolerated, but it can cause kidney toxicity in susceptible individuals and bone loss soon after starting treatment.

TAF (part of the Descovy, Genvoya, and Odefsey coformulations) is a pro-drug that delivers its active agent more efficiently to HIV-infected cells. TAF produces adequate intracellular levels with much lower doses, which means lower concentrations in the blood plasma and less drug exposure for the kidneys, bones, and other organs and tissues.

At the 2015 CROI researchers presented 48-week results from a pair of Phase 3 studies comparing single-tablet regimens containing TAF and TDF used for initial antiretroviral therapy (ART). At this year’s meeting Jose Arribas from La Paz University Hospital in Madrid gave an update with 144-week data.

 

Study 104 and Study 111 together included 1733 previously untreated people; most were men and the median age was 34 years. They had well-controlled HIV disease with a median CD4 T-cell count of approximately 400 cells/mm3 and normal kidney function with a median estimated glomerular filtration rate (eGFR) of approximately 115 mL/min.

Participants were randomly assigned to start a once-daily single-tablet regimen containing elvitegravir, cobicistat and emtricitabine with either 25 mg TAF or 300 mg TDF (Genvoya or Stribild).

At 48 weeks 92% of people in the TAF arm and 90% in the TDF arm achieved HIV RNA <50 copies/mL, showing that TAF was non-inferior to TDF. At 144 weeks the viral suppression rates were 84% and 80%, respectively, and at this point the TAF regimen was statistically superior to the TDF combo. 12 participants (1.4%) in each arm experienced virological failure with drug resistance.

The 48-week data showed that overall drug safety profiles were similar in both arms, with few participants discontinuing treatment due to adverse events (8 on TAF and 13 on TDF). But while most discontinuations for this reason happened early in the TAF arm, they continued to occur over time in the TDF arm, so by week 144 there was a significant difference in favour of TAF.

Most notably, there were 12 kidney-related events leading to discontinuation — including 4 cases of renal tubulopathy — in the TDF arm but none in the TAF arm. Likewise, 6 people in the TDF arm but none in the TAF arm stopped early due to bone-related events. Changes in renal biomarkers were significantly smaller and there was significantly less hip and spine bone loss in the TAF arm. Fasting lipids increased more among people on TAF, however.

“These longer-term data support the use of elvitegravir/cobicistat/emtricitabine/TAF as a safe, well tolerated and durable regimen for initial and on-going HIV-1 treatment,” the researchers concluded.

Switching to TAF with Low Bone Density

In additions to its benefits for first-line therapy, studies have also shown better outcomes when people on ART with undetectable viral load switch from TDF to TAF.

In 2015 researchers reported 48-week results from Study 109, a Phase 3 trial in which people with viral suppression on a TDF-containing regimen either stayed on the same therapy or switched to the Genvoya TAF regimen. This study included 1436 participants, mostly men, with a median age of about 41 years, median CD4 count of approximately 670 cells/mm3 and a median eGFR of about 106 mL/min.

After 48 weeks, 97% of people who switched to the TAF coformulation had undetectable viral load compared with 93% of those who stayed on their existing regimen — a significant difference in favour of TAF. People who switched to TAF experienced improvements in kidney function biomarkers while those who stayed on TDF worsened, and those in the TAF arm were less likely to discontinue therapy due to kidney-related adverse events.

In the overall study population spine bone mineral density (BMD) rose by a mean of +1.79% in the TAF arm but fell by -0.28% in the TDF arm; the corresponding changes in hip BMD were +1.37% and -0.26%, with both differences being statistically significant. People who switched to TAF saw significant reductions in osteoporosis (brittle bones) and osteopenia (milder bone loss).

At CROI Todd Brown from Johns Hopkins University presented 96-week bone data from participants who started with low bone density in Study 109 and Study 112, a single-arm, non-randomized study in which participants made the same TDF to TAF regimen switch.

Of the 1117 total participants in the 2 trials, 214 (19%) had low BMD at baseline, based on comparison with norms of a population of the same sex and age. Low BMD was defined as having a T-score < -2.0 at the lumbar spine, total hip, or femoral neck (narrow part of the hip joint); 43% had T-scores < -2.5, indicating osteoporosis. Most (85%) were men and the median age was 46 years. Two-thirds had normal body weight, a quarter were smokers, and half used protease inhibitors — factors also associated with bone health.

The researchers analysed BMD changes according to DEXA scans, changes in T-scores, proportion with osteopenia or osteoporosis, and bone turnover biomarkers including procollagen 1 intact N-terminal propeptide (P1NP) and C-terminal telopeptide (CTX).

At 96 weeks after switching from TDF to TAF, BMD increased by about 2.5% at both the lumbar spine and total hip. Over a quarter of participants (27%) experienced at least a 5% increase in spine bone density and 16% had at least a 5% gain at the hip. Among 86 participants who started with osteoporosis, 23% no longer met the criteria at week 96, though they still had osteopenia.

People with excessive phosphate excretion in the urine and higher bone turnover biomarkers were more likely to experience at least a 5% increase in BMD. People with lower hip BMD at baseline saw larger gains, though this was not the case for the spine.

“Switching from TDF to TAF may be an important treatment strategy to increase bone mineral density in those at the highest fracture risk,” the researchers concluded. “Baseline urinary phosphate wasting or high bone turnover may identify TDF-treated HIV-infected patients with low BMD who may benefit the most from a switch to TAF.”

Further Reading: Fact Sheet: Bone Problems and HIV www.aidsmap.com/page/3117279

 

References

JR Arribas, M Thompson, PE Sax, et al. Significant efficacy and long-term safety difference with TAF-based STR in naive adults. Conference on Retroviruses and Opportunistic Infections. Seattle, February 13-16, 2017. Abstract 453.T Brown, MT Yin, S Gupta, et al. Switching from TDF to TAF in HIV-infected adults with low BMD: a pooled analysis. Conference on Retroviruses and Opportunistic Infections. Seattle, February 13-16, 2017. Abstract 683.

Source: Article by Liz Highleyman. Published on Thursday, 16 March 2017   http://www.hivandhepatitis.com/hiv-related-conditions/hiv-bone-loss-osteoporosis/6024-croi-2017-bone-density-improves-in-people-who-switch-from-tenofovir-df-to-tenofovir-alafenamide